Extended Data Fig. 4: Effect of huIFNε, huIFNβ and muIFNε in PDX models of HGSOC.
From: Interferon-ε is a tumour suppressor and restricts ovarian cancer
Two PDX models of HGSOC were performed using tumours obtained from two different patients, as described in the Methods. PDX #111 demonstrated induction of ISGs with huIFNε treatment and was designated a “responder” to IFNε. (a) Total number of metastatic deposits found in the peritoneal cavity in mice bearing “responder” PDX #111 tumours, treated with either PBS or equivalent IU of huIFNβ, huIFNε or muIFNε. Data is presented as mean ± SD of individual mice. Significance was determined by Mann-Whitney U test. (b,c) Plots of log2 fold changes of significantly differentially expressed genes in tumour cells from (b) huIFNε vs huIFNβ and (c) huIFNε vs muIFNε treated mice, highlighting significantly differentially up- and down-regulated genes with huIFNε treatment (red and blue respectively). (d) Heat map of RNA-seq analysis of mice bearing tumours from “responder” PDX #111 and “non-responder” PDX #183, showing all genes identified from the Reactome IFN alpha/beta signalling gene set. Genes in bold were significantly induced by huIFNε in the “responder” PDX and also had significantly higher basal levels in the “non-responder” PDX (scale truncated to ± 6). For PDX #111, n = 6 mice per treatment group. For PDX #183, n = 7 mice treated with PBS or huIFNβ, n = 6 mice treated with huIFNε or muIFNε.
